This company develops next-generation radiopharmaceuticals utilizing the copper radioisotope 64Cu for cancer diagnosis and therapy. Their focus is on creating domestic radiopharmaceuticals that enable "visible" cancer treatment for intractable cancers. This work aims to connect advanced science with medicine to contribute to patient health and well-being.
Funding
Funding not disclosed
Founders
Product
Problem
Refractory cancers pose significant challenges due to their resistance to conventional treatments, resulting in limited therapeutic options and poor patient outcomes. Effective diagnosis and targeted therapy are crucial for improving treatment efficacy in these difficult-to-treat malignancies.
Solution
LinkMed develops radiopharmaceuticals based on the copper radioisotope 64Cu-ATSM for both the diagnosis and treatment of refractory cancers. 64Cu-ATSM enables targeted delivery of radiation to cancer cells, potentially improving treatment efficacy while minimizing damage to healthy tissues. This theranostic approach allows for both visualization and treatment of tumors using the same agent, facilitating personalized medicine strategies. The company focuses on developing innovative radiopharmaceuticals to address unmet needs in oncology.
Target Audience
The primary target audience includes oncologists, nuclear medicine physicians, and patients with refractory cancers who require advanced diagnostic and therapeutic options.
Features
- Utilizes the copper radioisotope 64Cu-ATSM for targeted cancer therapy.
- Theranostic approach enables both diagnosis and treatment using the same radiopharmaceutical.
- Designed for improved treatment efficacy in refractory cancers.
- Focus on personalized medicine strategies through targeted therapy.